Business Context and Reporting Period
Company: Nature's Sunshine Products, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2000
Business Overview: The Company operates in the nutritional supplement market through an independent sales force of Managers and Distributors. Operations are divided into four segments: Domestic (U.S.), Latin America, Asia Pacific, and Other regions.
Key Financial Metrics
Amounts in thousands, except per-share data.
| Metric | Three Months Ended June 30, 2000 |
Six Months Ended June 30, 2000 |
|---|---|---|
| Sales | $78,381 | $158,358 |
| Net Income | $4,891 | $9,387 |
| Operating Income | $7,698 | $14,633 |
| Net Cash from Operating Activities | N/A | $13,324 |
| Cash and Cash Equivalents (Ending) | $23,880 | $23,880 |
| Short-Term Debt | $698 | $698 |
| Diluted EPS | $0.29 | $0.55 |
Material Changes vs. Prior Period
- Sales Growth: Sales increased 9.4% for the quarter and 10.1% for the six-month period compared to the prior year. This growth was driven by international operations, which rose 40% (quarter) and 38% (six months).
- Segment Performance:
- Domestic: Sales declined 7% (quarter) and 4% (six months) due to increased product and price competition.
- Asia Pacific: Sales surged 182% (quarter) and 183% (six months), driven by demand in South Korea.
- Latin America: Sales grew 17% (quarter) and 14% (six months), aided by stable currencies and growth in Mexico and Brazil.
- Profitability: Net income increased 2.0% for the quarter ($4,891 vs. $4,796) but decreased 4.1% for the six-month period ($9,387 vs. $9,786). Operating income margins compressed slightly for the six-month period (9.2% vs. 10.5% prior year) due to higher SG&A expenses relative to sales.
- Balance Sheet: Total assets increased to $117.3 million from $107.4 million. Accrued liabilities rose by approximately $4.0 million, primarily due to sales conventions and travel programs.
Guidance, Outlook, and Risks
- Outlook: Management expects cost of goods sold and volume incentives to remain relatively constant as a percentage of sales for the remainder of 2000. SG&A expenses are expected to decrease slightly as a percentage of sales for the full year.
- Capital Projects: A facility expansion for manufacturing, R&D, and quality assurance is planned to begin in Q3 2000. The project is estimated to cost $14 million and take two years, funded by working capital.
- Liquidity: The Company maintains no credit facility but believes external funding could be obtained on competitive terms if necessary. Management expects working capital requirements to be met by internal funds.
- Risks:
- Continued strong competition in the domestic market.
- Foreign currency translation adjustments negatively impacted comprehensive income.
- Potential adverse effects on long-term liquidity in the event of a prolonged economic downturn or decreased product demand.
- Legal: The Company is a defendant in various incidental lawsuits; management believes these will not have a material effect on financial position.
Investor Verification Checklist
- Domestic Sales Decline: Verify the sustainability of the 7% domestic sales drop and the impact of competitive pricing on future margins.
- International Growth Quality: Assess the durability of the 180%+ growth in Asia Pacific and whether it is driven by one-time promotional programs or structural market expansion.
- Capital Expenditure Funding: Confirm the Company's ability to fund the $14 million facility expansion without external debt, given the current cash position and operating cash flow.
- Share Repurchases: Note the active buyback program (379,000 shares repurchased in six months) and its impact on earnings per share versus cash burn.
- Accrued Liabilities: Review the $4.0 million increase in accrued liabilities to ensure it aligns with expected payout schedules for sales conventions.